Packages (Simulation)
Image (II)
-
Figure. SDS-PAGE
-
WB Image
Quality Guarantee
Instruction Manual
Certificate
Active Fibroblast Growth Factor 23 (FGF23)
ADHR; HYPF; HPDR2; PHPTC; Phosphatonin; Tumor-derived hypophosphatemia-inducing factor
- Product No.APA746Hu03
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
- Traits Freeze-dried powder
- Purity> 95%
- Isoelectric Point7.9
- ApplicationsCell culture; Activity Assays.
- DownloadInstruction Manual
- UOM 10µg50µg 200µg 1mg 5mg
- FOB
US$ 270
US$ 675
US$ 1350
US$ 4050
US$ 10125
For more details, please contact local distributors!
ACTIVITY TEST
Fibroblast growth factor 23 or FGF23 is a member of the fibroblast growth factor (FGF) family which is responsible for phosphate and vitamin D metabolism. The main function of FGF23 seems to be regulation of phosphate concentration in plasma. FGF23 decreases the reabsorption and increases excretion of phosphate and suppress 1-alpha-hydroxylase, reducing its ability to activate vitamin D and subsequently impairing calcium absorption. Besides, Fibroblast Growth Factor Receptor 1 (FGFR1) has been identified as an interactor of FGF23, thus a binding ELISA assay was conducted to detect the interaction of recombinant human FGF23 and recombinant human FGFR1. Briefly, FGF23 were diluted serially in PBS, with 0.01% BSA (pH 7.4). Duplicate samples of 100 µl were then transferred to FGFR1-coated microtiter wells and incubated for 1h at 37℃. Wells were washed with PBST and incubated for 1h with anti-FGF23 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were aspirated and washed 5 times. With the addition of substrate solution, wells were incubated 15-25 minutes at 37℃. Finally, add 50 µL stop solution to the wells and read at 450nm immediately. The binding activity of FGF23 and FGFR1 was shown in Figure 1, and this effect was in a dose dependent manner. the EC50 for this effect is 0.0191 ug/mL.
USAGE
Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.
STORAGE
Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.
STABILITY
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.
GIVEAWAYS
INCREMENT SERVICES
-
BCA Protein Quantification Kit
-
Molecular Mass Marker for Protein
-
Monoclonal Antibody Customized Service
-
Polyclonal Antibody Customized Service
-
Protein Activity Test Experiment Service
-
Electrophoretic Mobility Shift Assay (EMSA) Experiment Service
-
Buffer
-
Lentivirus Packaging Experiment Service
-
Adenovirus Packaging Experiment Service
-
Real Time PCR Experimental Service
-
Spike RBD Protein (S-RBD)
-
Protein G
-
Protein A
| Magazine | Citations |
| Journal of international medicine | Prognostic impact of renal function in precapillary pulmonary hypertension Pubmed: 24011362 |
| BMC Nephrology | FGF-23 associated with the progression of coronary artery calcification in hemodialysis patients Pubmed: 24180481 |
| Journal of Clinical Densitometry | Lower Fibroblast Growth Factor 23 Levels in Young Adults With Crohn Disease as a Possible Secondary Compensatory Effect on the Disturbance of Bone and Mineral Metabolism Pubmed: 23623649 |
| J Intern Med. | Prognostic impact of renal function in precapillary pulmonary hypertension. Pubmed:24011362 |
| Journal of Bone and Mineral Research | Adverse effects of osteocytic constitutive activation of ?-catenin on bone strength and bone growth Pubmed:25639729 |
| Nefrologia | Fibroblast growth factor is associated to left ventricular mass index, anemia and low values of transferrin saturation El factor de crecimiento fibroblástico está asociado con el índice de masa ventricular izquierda, anemia y niveles bajos de saturación de la transferrina PubMed: 26394828 |
| Medicine (Baltimore) | An Attempt to Evaluate Selected Aspects of “Bone–Fat Axis” Function in Healthy Individuals and Patients With Pancreatic Cancer PubMed: 26266370 |
| Ann Biol Clin (Paris) | Les biomarqueurs des calcifications vasculaires: quelles limites analytiques pour leur transfert de la recherche bioclinique à la pratique? PubMed: 26069069 |
| Scandinavian Journal of Gastroenterology | High-dose fast infusion of parenteral iron isomaltoside is efficacious in inflammatory bowel disease patients with iron-deficiency anaemia without profound changes in phosphate or fibroblast growth factor 23 Pubmed:27326766 |
| PLOS ONE | Prostaglandin-E2 Mediated Increase in Calcium and Phosphate Excretion in a Mouse Model ofDistal Nephron Salt Wasting. pubmed:27442254 |
| Journal of Laboratory Diagnostics | Evaluation of concentration fibroblast growth factor FGF-23 in hemodialysed patients and after kidney transplantation publication:312592751 |
| Journal of Integrative Nephrology & Andrology | Associations between serum fibroblast growth factor 23 level and intradialytic hypotension in hemodialysis patients issn:2394-2916 |
| Journal of Renal Nutrition | ADAM17, a New Player in the Pathogenesis of Chronic Kidney Disease-Mineral and Bone Disorder. pubmed:29056164 |
| Experimental Biology and Medicine(Maywood) | Effect of cross-linked chitosan iron (III) on vascular calcification in uremic rats Pubmed:29763365 |
| Psychiatry Research | Cerebrospinal fluid FGF23 levels correlate with a measure of impulsivity Pubmed:29677623 |
| BMC Pediatrics | Serum and urine FGF23 and IGFBP-7 for the prediction of acute kidney injury in critically ill children Pubmed:29907141 |
| Medical Science Monitor | Effect of Salt Intervention on Serum Levels of Fibroblast Growth Factor 23 (FGF23) in Chinese Adults: An Intervention Study Pubmed:29608553 |
| International Journal of Chronic Obstructive Pulmonary Disease | Disconnection of pulmonary and systemic arterial stiffness in COPD Pubmed:29881265 |
| Saudi journal of kidney diseases and transplantation | Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients Pubmed:29970732 |
| Nephrology Dialysis Transplantation | High-serum phosphate and parathyroid hormone distinctly regulate bone loss and vascular calcification in experimental chronic kidney disease Pubmed: 30189026 |
| BioFactors | Alteration in serum concentrations of FGF19, FGF21, and FGF23 in patients with urothelial carcinoma Pubmed: 30334297 |
| Biological Trace Element Research | Altered Mineral Metabolism and Disequilibrium Between Calcification Promoters and Inhibitors in Chronic Hemodialysis Patients Pubmed: 30847765 |
| Clin Implant Dent Relat Res. | Evaluation of FGF‐23 and 25(OH)D3 levels in peri‐implant sulcus fluid in peri‐implant health and diseases Pubmed: 31407857 |
| JACC-Cardiovascular Imaging | PREVALANCE AND PROGRESSION OF CARDIOVASCULAR CALCIFICATIONS IN HAEMODIALYSIS PATIENTS Pubmed: 28797410 |
| Saudi J Kidney Dis Transpl | Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease Pubmed: 31696838 |
| Biomedicine & Pharmacotherapy | MiRNA-192-5p attenuates airway remodeling and autophagy in asthma by targeting MMP-16 and ATG7 Pubmed: 31918268 |
| Is Serum FGF-23 Associated with Subclinic Atherosclerosis in Patients with AA Amyloidosis? | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS | |
| THE RELATIONSHIP BETWEEN ARTERIAL STIFFNESS AND 25-(OH) VITAMIN D, FGF 23 IN MAINTENANCE HEMODIALYSIS PATIENTS KRON?K ¡ | |
| Calcif Tissue Int | The Measurement and Interpretation of Fibroblast Growth Factor 23 (FGF23) Concentrations Pubmed:35665817 |
| European Journal of Medical Genetics | Genetic and clinical profile of patients with hypophosphatemic rickets Pubmed:35738466 |
| African Health Sciences | Fibroblast Growth Factor 23 (FGF 23) and intact parathyroid hormone (iPTH) as markers of mineral bone disease among Nigerians with non-diabetic kidney disease |